×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
DNTH – dianthus therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
DNTH
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/11
10:22 am
dnth
Dianthus Therapeutics, Inc. (NASDAQ: DNTH) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
Low
Report
Dianthus Therapeutics, Inc. (NASDAQ: DNTH) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
11/11
09:02 am
dnth
Dianthus Therapeutics, Inc. (NASDAQ: DNTH) had its price target raised by analysts at Oppenheimer Holdings Inc. from $48.00 to $52.00. They now have an "outperform" rating on the stock.
High
Report
Dianthus Therapeutics, Inc. (NASDAQ: DNTH) had its price target raised by analysts at Oppenheimer Holdings Inc. from $48.00 to $52.00. They now have an "outperform" rating on the stock.
11/8
01:45 pm
dnth
Dianthus Therapeutics, Inc. (NASDAQ: DNTH) had its price target raised by analysts at Raymond James from $51.00 to $56.00. They now have an "outperform" rating on the stock.
Low
Report
Dianthus Therapeutics, Inc. (NASDAQ: DNTH) had its price target raised by analysts at Raymond James from $51.00 to $56.00. They now have an "outperform" rating on the stock.
11/7
07:48 pm
dnth
Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
Low
Report
Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
11/7
04:01 pm
dnth
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results
Low
Report
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results
11/4
07:00 am
dnth
Dianthus Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences
Low
Report
Dianthus Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences
10/15
07:00 am
dnth
Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting
High
Report
Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting
10/3
08:17 am
dnth
Dianthus Therapeutics, Inc. (NASDAQ: DNTH) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $48.00 price target on the stock.
Medium
Report
Dianthus Therapeutics, Inc. (NASDAQ: DNTH) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $48.00 price target on the stock.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/22
04:42 pm
dnth
Form SC 13G Dianthus Therapeutics, Filed by: TCG Crossover GP II, LLC
Medium
Report
Form SC 13G Dianthus Therapeutics, Filed by: TCG Crossover GP II, LLC
11/14
05:49 pm
dnth
Form SC 13G/A Dianthus Therapeutics, Filed by: 5AM Partners VII, LLC
Medium
Report
Form SC 13G/A Dianthus Therapeutics, Filed by: 5AM Partners VII, LLC
11/14
05:48 pm
dnth
Form SC 13G/A Dianthus Therapeutics, Filed by: Venrock Healthcare Capital Partners III, L.P.
Medium
Report
Form SC 13G/A Dianthus Therapeutics, Filed by: Venrock Healthcare Capital Partners III, L.P.
11/8
05:32 pm
dnth
Form SC 13G Dianthus Therapeutics, Filed by: BlackRock, Inc.
High
Report
Form SC 13G Dianthus Therapeutics, Filed by: BlackRock, Inc.
11/7
04:07 pm
dnth
Form 10-Q Dianthus Therapeutics, For: Sep 30
Medium
Report
Form 10-Q Dianthus Therapeutics, For: Sep 30
11/7
04:04 pm
dnth
Form 8-K Dianthus Therapeutics, For: Nov 07
Low
Report
Form 8-K Dianthus Therapeutics, For: Nov 07
10/24
02:02 pm
dnth
Form SC 13G Dianthus Therapeutics, Filed by: BlackRock, Inc.
Low
Report
Form SC 13G Dianthus Therapeutics, Filed by: BlackRock, Inc.
10/21
04:20 pm
dnth
Form RW Dianthus Therapeutics,
Medium
Report
Form RW Dianthus Therapeutics,
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: